PIK3CA and cancer: A more promising approach seems to be to target the PI3K/Akt/mTOR pathway at multiple sites, as well as along related pathways, as a means to maximize efficacy, while reducing side effects; it may also be possible to identify inhibitors that target aberrant PI3K/Akt/mTOR pathways exclusively within cancer cells.